GLP1R agonists like lixisenatide, exenatide, or semaglutide limit the progression of motor dysfunction in Parkinson’s disease.
Neuroscience
Posted inNeuroscience, New Drugs, Rare/Orphan Diseases, Regulatory
Duvyzat: Givinostat for Duchenne Muscular Dystrophy Treatment
Oral givinostat delays the progression of DMD.
Posted inNeuroscience, New Drugs, Rare/Orphan Diseases, Regulatory
Relyvrio/Albrioza: New Drug for Amyotrophic Lateral Sclerosis Treatment
Amylyx Pharmaceuticals proposed mixture of sodium phenylbutyrate and tauroursodeoxycholic acid for ALS treatment.
Posted inNeuroscience, New Drugs, Rare/Orphan Diseases, Regulatory
Skysona: Gene Therapy for Cerebral Adrenoleukodystrophy
A single dose of the elivaldogene autotemcel will cure a deadly disease.
Posted inNeuroscience, New Drugs, Regulatory
Auvelity: New Antidepressant for Most Severe Depression
Dextromethorphan and bupropion: A powerful drug combination that will help with depression that cannot be treated with standard antidepressants.
Posted inClinical Trials, Neuroscience, Rare/Orphan Diseases
Qalsody: New Drug for Amyotrophic Lateral Sclerosis with SOD1 Mutation
Tofersen and the mixed results of treatment for the deadly neurodegenerative disease.
Posted inClinical Trials, Neuroscience, Rare/Orphan Diseases
Alsitek: New Drug for ALS
Oral masitinib doubles the life in patients with amyotrophic lateral sclerosis.